Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: Consensus Outlook

Product Code:
Last Updated:
April 2014
PDF + Excel

The worldwide hepatitis C (HCV) market is forecasted to grow to $17.7 billion in 2017.  The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.

Therapy Trends Hepatitis C: Consensus Outlook provides an in-depth analysis of the products players and events that will shape the future HCV market.

  • An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
  • An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017

Click here for sample pages

Key Benefits

  • Evaluate future sales forecasts and predicted market growth
  • Map your market parameters and chart commercial prospects
  • Assess market share by company and product
  • Tailor your strategic and investment focus based on the competition
  • Set proactive launch and branding strategies

Forecast Analysis Report and Data Model

The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.  

  • Historical HCV sales from 2007–2012
  • Forecast HCV sales from 2013-2017
  • Key competitors and drug developers
  • Predicted product positioning
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Comparative clinical trial results

Click here for sample pages

FirstWord’s HCV forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.

  • Market size
  • Product sales
  • Company forecasts
  • Company, brand, and drug class
  • Mechanism of action Future events


Consensus Outlook reports provide annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections–produced either internally or by other third parties–can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved